Product Information
JORNAY PM 100 MG CAPSULE is a brand product labeled by Ironshore Pharmaceuticals Inc., priced at $15.3960 per EA under NDC 71376020503. Its NADAC has been published 259 times since Oct 20, 2021.
FDA first approved this application on Aug 8, 2018.
The High Outlier badge above means this manufacturer's average price in the Methylphenidate Hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/1
Manufacturer
Ironshore Pharmaceuticals Inc.NDC
71376020503
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA209311FDA Approved
8/8/2018
On Market Since
6/1/2019
Pharmacological Classes
Price Statistics
The NADAC for JORNAY PM 100 MG CAPSULE has been published 259 times since Oct 20, 2021, and over the history we have for it it has risen 19.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.3960 per EA |
|---|---|
| All-time high | $15.4212 (Jun 10, 2026) |
| All-time low | $12.8656 (Oct 20, 2021) |
| 52-week high | $15.4212 |
| 52-week low | $14.9600 |
| Median price | $14.5188 |
| Average price | $14.2489 |
| Largest weekly change | +5.0% (Jan 17, 2024) |
| Weeks tracked | 259 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methylphenidate Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ironshore Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of JORNAY PM 100 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for JORNAY PM 100 MG CAPSULE, manufactured by Ironshore Pharmaceuticals Inc., is $15.3960 per EA (NDC 71376020503), effective Sep 30, 2026.
How has the price of JORNAY PM 100 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for JORNAY PM 100 MG CAPSULE has risen 19.7%. It has been tracked across 259 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for JORNAY PM 100 MG CAPSULE?
Since Oct 20, 2021, the NADAC for JORNAY PM 100 MG CAPSULE has ranged from a low of $12.8656 (Oct 20, 2021) to a high of $15.4212 (Jun 10, 2026), with a median of $14.5188 per EA.
Are there cheaper alternatives to JORNAY PM 100 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of JORNAY PM 100 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures JORNAY PM 100 MG CAPSULE?
JORNAY PM 100 MG CAPSULE (NDC 71376020503) is labeled by Ironshore Pharmaceuticals Inc., and CMS classifies it as a brand product.